Zytiga (abiraterone acetate; Johnson & Johnson/AstraZeneca) is a small molecule oral irreversible inhibitor of the 17 alpha-hydroxylase enzyme which catalyzes the hydroxylation of intermediates involved in testosterone synthesis. Prostate cancer cell growth is commonly driven by hormones, and as Zytiga inhibits the rate-limiting enzyme in androgen synthesis, it blocks testosterone production activity in the testes, adrenal glands, and prostate, while preserving adrenal sufficiency.
TABLE OF CONTENTS
4 Product Profiles
4 Zytiga : Prostate cancer
LIST OF FIGURES
12 Figure 1: Zytiga for prostate cancer – SWOT analysis
13 Figure 2: Datamonitor Healthcare’s drug assessment summary of Zytiga for prostate cancer
14 Figure 3: Datamonitor Healthcare’s drug assessment summary of Zytiga for prostate cancer
17 Figure 4: Zytiga sales for prostate cancer across the US, Japan, and five major EU markets, by country, 2017–26
LIST OF TABLES
4 Table 1: Zytiga drug profile
6 Table 2: Zytiga Phase III data in prostate cancer
10 Table 3: Zytiga Phase III trials in prostate cancer
18 Table 4: Zytiga sales for prostate cancer across the US, Japan, and five major EU markets, by country ($m), 2017–26
Pharma Intelligence UK Limited is a company registered in England and Wales with company number 13787459 whose registered office is Suite 1, 3rd Floor, 11 - 12 St. James's Square, London, England, SW1Y 4LB. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.